Alpha-Lipoic Acid for Women: Are There Any Special Considerations?
Alpha-lipoic acid (ALA) is a popular antioxidant supplement marketed for weight management, energy and "metabolic health". Women often encounter it in products aimed at PCOS, skin or fat loss. Are there any female-specific benefits or risks? Our editorial team looked at what the research actually shows.
What alpha-lipoic acid does
Alpha-lipoic acid is a sulphur-containing fatty acid made in small amounts in mitochondria, where it acts as a co-factor for enzymes involved in energy production. It is found in foods such as spinach, broccoli and organ meats, but only in tiny quantities.
As a supplement, ALA is absorbed and partly converted to dihydrolipoic acid. Both forms act as antioxidants and can help regenerate other antioxidants such as vitamins C and E and glutathione. It also appears to influence insulin signalling and glucose uptake into cells.
Supplements contain either the racemic mixture (R/S-ALA) or the natural R-form. R-ALA is better absorbed in some studies, but most clinical trials used the racemic form, so the difference in practice is uncertain.
In Germany and several other European countries, ALA is licensed as a medicine for diabetic neuropathy, based on trials such as SYDNEY 2, which used 600 mg daily orally. In the UK it is sold as a food supplement with no authorised health claims.
Weight management and body composition
ALA is frequently marketed as a fat-loss aid. A 2018 meta-analysis by Namazi and colleagues found a small but statistically significant reduction in body weight and BMI compared with placebo, typically measured in fractions of a kilogram to a little over a kilogram.
The effect is modest and comparable in men and women. It is not a substitute for a sensible diet and training plan, and many studies included people with obesity or diabetes rather than active, healthy women.
Some research suggests ALA may slightly reduce appetite through effects on the hypothalamus, an idea based mainly on animal work. Human data are inconsistent, and there is no evidence that ALA selectively targets "female" fat distribution.
In practice, women in a calorie deficit who train regularly are unlikely to notice a meaningful difference from ALA alone. Its value for weight loss should be considered marginal at best.
PCOS and insulin sensitivity
Polycystic ovary syndrome affects roughly one in ten women in the UK and is often associated with insulin resistance. Because ALA can improve insulin sensitivity, it has been tested in women with PCOS.
A small study by Masharani and colleagues in 2010 found improved insulin sensitivity and some changes in triglycerides in lean women with PCOS given controlled-release ALA. Several Italian studies have combined ALA with inositols, reporting improvements in menstrual regularity and metabolic markers.
These results are encouraging but preliminary. Most studies were small, short and lacked robust placebo controls. ALA is not part of standard UK PCOS management, which emphasises lifestyle measures and, where appropriate, medicines such as metformin or hormonal treatment.
Women with PCOS considering ALA should discuss it with their GP, particularly if they are taking metformin or other glucose-lowering medicines, as the combination could, in theory, lower blood glucose further.
Pregnancy, thyroid and other female-specific questions
ALA has been used in pregnancy in some European clinical settings. A retrospective observational study by Parente and colleagues found no signal of harm in women who took it during pregnancy. However, observational data cannot prove safety, and no UK body recommends ALA during pregnancy or breastfeeding.
Hypothyroidism is more common in women. Animal studies have raised the possibility that ALA might interfere with conversion of thyroid hormone, and some clinicians advise checking thyroid function in people on levothyroxine who start high-dose ALA. Human data are limited.
| Situation | Main consideration | Suggested approach |
|---|---|---|
| Pregnancy, breastfeeding | No controlled safety data | Avoid unless prescribed by a specialist |
| Hypothyroidism on levothyroxine | Possible interference, uncertain | Discuss with GP; consider thyroid tests |
| Diabetes or PCOS on metformin | Additive glucose lowering | Monitor glucose; medical advice first |
| Chemotherapy | Antioxidants may interact with treatment | Only with oncologist approval |
| Low vitamin B1 (e.g. high alcohol intake) | Theoretical risk with high doses | Correct deficiency first |
A rare but important reaction is insulin autoimmune syndrome (Hirata disease), in which the body produces antibodies against insulin, causing episodes of hypoglycaemia. Cases have been linked to ALA in people with a particular genetic susceptibility, including Europeans, as described by Gullo and colleagues in 2014.
Any woman taking ALA who experiences unexplained shakiness, sweating, confusion or fainting should stop the supplement and seek medical advice promptly, as these may be signs of low blood glucose.
Practical use and safety
Trials have commonly used 300–600 mg per day, sometimes up to 1,200 mg or more in neuropathy research. For general use, most supplements provide 200–600 mg per serving.
- take ALA on an empty stomach, about 30 minutes before a meal, as food reduces absorption;
- start at a lower dose to assess tolerance;
- expect a noticeable smell in urine at higher intakes, which is harmless;
- stop if you develop rash, itching or signs of low blood glucose.
The most common side effects are mild nausea, stomach discomfort, skin rash and, occasionally, headache. Serious adverse effects are rare at typical doses in healthy adults.
ALA is not on the WADA Prohibited List. As with any supplement, women who compete in tested sport should choose products with independent batch testing to reduce contamination risk.
Finally, check whether your multivitamin or "metabolic" blend already contains ALA, so that you do not take more than you intend. Products aimed at skin health or energy sometimes include it without highlighting it on the front of the pack.
Conclusions of the editorial team
Alpha-lipoic acid works similarly in men and women. Its strongest evidence is for diabetic neuropathy, with smaller effects on insulin sensitivity and only a modest impact on body weight.
Women with PCOS may see metabolic benefits, but the research is early and ALA does not replace standard care. Pregnancy data are reassuring but insufficient to recommend routine use.
Female-relevant cautions include thyroid medication, glucose-lowering treatment and the rare insulin autoimmune syndrome. Medical advice is sensible before starting.
Our editorial team has also written about myo-inositol and PCOS, iron needs in female athletes, and the evidence on antioxidant supplements and training adaptation.
References
- Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 2009;1790(10):1149–1160.
- Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29(11):2365–2370.
- Namazi N, Larijani B, Azadbakht L. Alpha-lipoic acid supplement in obesity treatment: a systematic review and meta-analysis of clinical trials. Clin Nutr. 2018;37(2):419–428.
- Masharani U, Gjerde C, Evans JL, Youngren JF, Goldfine ID. Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome. J Diabetes Sci Technol. 2010;4(2):359–364.
- Gullo D, Evans JL, Sortino G, Goldfine ID, Vigneri R. Insulin autoimmune syndrome (Hirata disease) in European Caucasians taking alpha-lipoic acid. Clin Endocrinol (Oxf). 2014;81(2):204–209.
- Parente E, Colannino G, Picconi O, Monastra G. Safety of oral alpha-lipoic acid treatment in pregnant women: a retrospective observational study. Eur Rev Med Pharmacol Sci. 2017;21(18):4219–4227.
